John B. Henneman
John B. Henneman, III joined the Board of Directors of Anika Therapeutics in September 2020. Mr. Henneman has more than 25 years of combined financial and operational management experience in the life sciences industry. Mr. Henneman served as Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation from October 2014 to July 2018, and as its Chief Administrative Officer from July 2018 to November 2018. Prior to joining NewLink Genetics, he served lntegra LifeSciences in various capacities between 1998 and 2014. Before becoming lntegra's Chief Financial Officer in 2007, Mr. Henneman served lntegra as General Counsel and Chief Administrative Officer, responsible at various times for lntegra's business development, regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs and the management of lntegra's surgical instruments business. Mr. Henneman serves on the boards of directors of SeaSpine Holdings Corporation, a publicly-held medical technology company, R1 RCM, Inc., a public company providing technology-enabled revenue cycle management services to healthcare providers, Aprea Therapeutics Inc., a publicly held biotechnology company, and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm and a consultant to SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies. Mr. Henneman received an A.B. in politics from Princeton University and a J.D. from the University of Michigan Law School. Mr. Henneman serves as the Chair of Anika’s Compensation Committee and a member Governance and Nominating Committee.